Case Report

Pulmonary Embolism after Moderna Vaccination in Kidney Transplant Patients: Two Case Reports and Literature Review

Wai-Nga Chan †, Chih-Shou Chen *,†, Dong-Ru Ho, Yun-Ching Huang , Jian-Hui Lin, Kuo-Tsai Huang and Yu-Liang Liu

Divisions of Urology, Department of Surgery, Chang Gung Medical Foundation, Chiayi City 613, Taiwan; ktwaiwaiwai@gmail.com (W.-N.C.); cv7589@cgmh.org.tw (D.-R.H.); pceokspspark@gmail.com (Y.-C.H.); jht790424@gmail.com (J.-H.L.); uro056085@gmail.com (K.-T.H.); gsuoro65818@gmail.com (Y.-L.L.)
* Correspondence: edward.urology@gmail.com; Tel.: +886-9-2295-8536
† These authors contributed equally to this work.

Abstract: Currently, the coronavirus disease 2019 (COVID-19) pandemic is still an ongoing and constant medical issue, and with upcoming new variants, vaccinations and boosters remain important. The safety of vaccines in patients after kidney transplantation is an essential problem, with thrombosis being one of the severe side effects and vaccine-induced immune thrombotic thrombocytopenia (VITT) revealed as the most commonly reported syndrome for thromboembolic events following COVID-19 vaccination. Here, we present two cases of kidney transplantation developing pulmonary embolism post-Moderna vaccination within 30 days without thrombocytopenia. The first case was a 52-year-old man with history of type II diabetes, hypertension and hyperlipidemia who had had cadaveric kidney transplantation in September 2008, where right leg swelling with claudication occurred 23 days after the second Moderna vaccination. The second case was a 57-year-old man with history of type II diabetes and glaucoma who had had living-related kidney transplantation in April 2013 and then complained of exertional dyspnea 26 days after administration of the third Moderna vaccine. The advantages of vaccination even in immunocompromised patients far outweigh the disadvantages, although clinicians must understand the risks of deep-vein thrombosis or even pulmonary embolism for such patients, which might not occur after just the first vaccination.

Keywords: kidney transplantation; COVID-19; Moderna vaccine; pulmonary embolism; deep vein thrombosis; immunosuppressant

1. Introduction

Currently, the COVID-19 pandemic is still an ongoing and constant medical issue, but with upcoming new variants, vaccinations and boosters remain important [1]. The safety of vaccines in patients after kidney transplantation, however, is an essential problem.

Common side effects after receiving the mRNA COVID-19 vaccine include pain or swelling at the injected site, tiredness, headache, fever, nausea or muscle pain. Thrombosis is one of the severe side effects after vaccination, with vaccine-induced immune thrombotic thrombocytopenia (VITT) being the most associated syndrome revealing the presence of platelet-activating antibodies against platelet factor 4 (PF4), a condition which clinically resembles severe heparin-induced thrombocytopenia [2–6]. Here we present two recipients who had previously undergone kidney transplantation and then developed pulmonary embolism without thrombocytopenia.

2. Detailed Case Description

2.1. Case 1

A 52-year-old man with history of type II diabetes mellitus, hypertension and hyperlipidemia had had cadaveric kidney transplantation in September 2008. His maintenance
Immunosuppressants were cyclosporin 25 mg/cap twice daily, mycophenolate sodium 180 mg/tab twice daily, methylprednisolone 4 mg/tab once daily and sirolimus 1 mg/tab once daily. He received 2 doses of the Moderna vaccine on the 19 November 2021 and the 23 December 2021.

Following this, he suffered from right low-extremity swelling and claudication 23 days after administration of the second vaccine, although no severe adverse effects were detected after the first dose. Medication was adjusted as mycophenolate sodium 180 mg from 1 piece twice daily to 2 pieces in the morning and 1 piece in the evening because of elevation of creatinine from 1.19 mg/dL to 1.35 mg/dL. Sirolimus level had been maintained at 6.6 ng/mL since September 2021, then mycophenolate sodium was changed back into 1 piece twice daily after December 2021 due to normal and stable creatinine. His average creatinine level in the past three months was 1.08 mg/dL, and the average sirolimus level was 7.1 ng/mL. Clinical characteristics during admission are shown in Table 1.

Table 1. Clinical characteristics of each patient.

| Variable                   | Case 1        | Case 2        |
|----------------------------|---------------|---------------|
| Hemoglobin, g/dL           | 14.7          | 16.7          |
| Platelet count, per µL     | 260,000       | 239,000       |
| Creatinine, mg/dL          | 1.0           | 1.24          |
| [Everolimus] *, ng/mL      | /             | 6.4           |
| [Sirolimus] *, ng/mL       | 6.8           | /             |
| [Cyclosporin] *, ng/mL     | /             | 64.9          |
| Troponin I, ng/mL          | /             | 0.039         |
| Pro-BNP, pg/mL             | /             | 7231.51       |
| D-dimer **, mg/L           | 3.59          | 1.10          |
| Fibrinogen, mg/dL          | 439.5         | 396           |
| Pulmonary embolism         | Yes           | Yes           |
| other thrombosis           | DVT ***       | No            |
| Symptom onset after vaccination, days | 23 (after 2nd dose) | 26 (after 3rd dose) |
| Anticoagulation therapy    | Enoxaparin/Enoxaban | Dabigatran |

[*] concentration of trough level. ** <0.5, 95% exclude pulmonary embolism. *** DVT: deep vein thrombosis.

Computed Tomography (CT) of chest and extremities (Figure 1) showed left pulmonary artery thrombosis and right femoral vein thrombosis in the first case.

He was treated with enoxaparin twice daily following admission for 5 days, then this was changed to 60 mg endoxaban once daily. To date, his symptoms have improved without dyspnea.

2.2. Case 2

A 57-year-old man with history of type II diabetes mellitus and glaucoma had had living-donor kidney transplantation in April 2013. His maintenance immunosuppressants were everolimus 0.25 mg/tab twice per day, mycophenolate mofetil 250 mg/tab twice per day, methylprednisolone 4 mg/tab and cyclosporin 25 mg/cap twice per day, respectively. He had three doses of Moderna vaccines on 11 August and 22 November in 2021, then 15 January in 2022.
Following the third dose, he complained of exertional dyspnea accompanied with bilateral leg edema 26 days later, although no severe adverse effects were detected after the previous two vaccinations. His average creatinine was 1.06 mg/dL, and average trough levels of cyclosporin and everolimus were 42.9 ng/mL and 4.3 ng/mL in the past three months, respectively. The clinical details when symptoms presented are shown in Table 1. He had not changed the immunosuppressants in the past 6 months; however, his drug level of cyclosporin had become elevated to 64.9 ng/mL with slight elevation of creatinine in the month he presented symptoms, so we tapered the cyclosporin to 25 mg daily. Pulmonary perfusion scan (Figure 2a) showed one segmental perfusion defect lesion at left lung revealed as a pulmonary embolism. Also, venography study (Figure 2b) showed negative for deep venous obstruction in bilateral low extremities.

He was treated at the outpatient department with a prescription for dabigatran 150 mg/cap twice daily and spironolactone 25 mg/tab daily. His symptoms have since improved during follow-up, and D-dimer has decreased to 0.19 mg/L.

In these two cases, they both had active social lives and lived independently. Their BMI were 22.9 and 22.3, respectively. The first case had quit smoking for the last 3 years, and the second case denied any smoking history; furthermore, they denied any recent trauma, personal or familial venous thromboembolism.

**Table 1.** He had not changed the immunosuppressants in the past 6 months; however, his drug level of cyclosporin had become elevated to 64.9 ng/mL with slight elevation of creatinine in the month he presented symptoms, so we tapered the cyclosporin to 25 mg daily. Pulmonary perfusion scan (Figure 2a) showed one segmental perfusion defect lesion at left lung revealed as a pulmonary embolism. Also, venography study (Figure 2b) showed negative for deep venous obstruction in bilateral low extremities.

He was treated at the outpatient department with a prescription for dabigatran 150 mg/cap twice daily and spironolactone 25 mg/tab daily. His symptoms have since improved during follow-up, and D-dimer has decreased to 0.19 mg/L.

In these two cases, they both had active social lives and lived independently. Their BMI were 22.9 and 22.3, respectively. The first case had quit smoking for the last 3 years, and the second case denied any smoking history; furthermore, they denied any recent trauma, personal or familial venous thromboembolism.

**Figure 1.** CT of chest and extremity: (a,b) left pulmonary artery thrombosis; (c,d) right femoral vein thrombosis. Arrow indicates thrombosis.
Vaccination is one of the most severe adverse effects after vaccinations. Both Adenovirus-based vaccines (AstraZeneca, Cambridge, UK; Johnson and Johnson, New Brunswick, NJ, USA) and mRNA-based vaccines (Pfizer, New York, NY, USA; Moderna) have been reported to cause thromboembolic events [5,7–9]. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is the most reported associated syndrome of thromboembolic events with presentations of thrombocytopenia, thrombosis and disseminated intravascular...
coagulation. Tobaiqy, Mansour et al. [9] reported the most potential thrombotic adverse events resulted from the Oxford–AstraZeneca vaccine.

Table 2. Types and vaccinations history in 32 recipients of kidney transplantation.

| Vaccines   | AstraZeneca | Moderna | BioNTech |
|------------|-------------|---------|----------|
| 1st Dose   | 6           | 24      | 2        |
| 2nd Dose   | 5           | 23      | 3        |
| 3rd Dose   | /           | 22      | 1        |
| Accumulated Dose | 11          | 69      | 6        |

In fact, the Eudra Vigilance database showed that thromboembolic events due to vaccinations were 58.1% for Oxford–AstraZeneca, 32% for Pfizer and 9.8% for Moderna. Furthermore, thrombosis with thrombocytopenia has appeared in all three vaccines, with higher rates in those who had received the Oxford–AstraZeneca vaccine. Maria Abbattista et al. [8] demonstrated a lower rate of unusual site thrombosis for mRNA as compared to the adenoviral vaccines. Cerebral vein thrombosis along with thrombocytopenia has been reported for all vaccines, ranging from 3–5% to 31–44% for mRNA and adenoviral vaccines, respectively. Therefore, mRNA vaccines could be a safer choice for occurrence of thrombotic adverse events and appear less-associated to VITT as clinical presentation.

To our knowledge, calcineurin inhibitors (CNI-Cyclosporin and Tacrolimus), mycophenolate mofetil (MMF) and mammalian target of rapamycin inhibitor (mTORi-sirolimus and everolimus) are commonly used immunosuppressants. The CNI-induced thrombotic microangiopathy (TMA) produced a syndrome similar to thrombotic thrombocytopenic purpura (TTP) with potentially pathogenic inhibitory antibodies against the von Willebrand factor (vWF), causing cleavage of protease ADAMTS13 and leading to platelet aggregation [10,11]. A single-center cohort study demonstrated an increased incidence of TMA in the combination of cyclosporin (CsA) and sirolimus (SRL) at 20.7% compared to CsA + MMF (3.7%), Tacrolimus + SRL (6.1%) and Tacrolimus + MMF (1.3%) [12]. Only one case report reveals the linkage between MMF and thrombosis with factor V Leiden, so more definite studies are needed to establish the true relationship between DVT and MMF [13]. In consideration of VITT thromboembolic events, immunosuppressant-related thrombosis has also been recorded with a common presentation of TTP as reported in cyclosporin-treated patients and in combination with CsA + SRL. However, drug induced TTP was less likely in our cases which did not have bleeding, anemia and thrombocytopenia, as they had not changed the dosages of CNI or mTORi in the past six months when the adverse events occurred.

Many studies have demonstrated a lower response rate among solid organ transplant patients than in the general population after vaccination [14,15]. In fact, COVID-19 infection after two doses of mRNA vaccines in kidney transplant patients has been reported in the real world [16].

As a consequence, clinicians should not neglect COVID-19 infection associated with thrombotic complications, especially in severe cases or inherited conditions [17]. Fiore JR et al. showed a case of rare homozygous prothrombin G20210A mutation in a young patient who developed severe pulmonary embolism and left iliac vein thrombosis after COVID infection [18]. In our two cases, the first case was tested before admission as per the policy of epidemic prevention in Taiwan government, but produced a negative result, although the second case was not tested because of outpatient department treatment protocol where no severe symptoms such as fever, headache, cough, rhinorrhea or diarrhea were presented.

In Taiwan, we have about 50 million vaccines that have been used already including 15 million doses of AstraZeneca vaccines (AZ), 17.5 million doses of Moderna vaccines, 15.5 million doses of BioNTech vaccines (BNT) and 2 million doses of MVC COVID-19 Vaccines (MCV) [19]. Overall reported severe adverse events from the Taiwan National Adverse Drug Reactions Reporting System number 8072 cases. Among all adverse events,
62 cases (62/50 million: 0.00012%) of idiopathic thrombocytopenic purpura (AZ for 44, Moderna for 14, BNT for 4) were reported with median age of 58.4 years and median onset of 14 days. Also, 71 cases (0.00014%) of thrombosis with thrombocytopenia syndrome (AZ for 59, Moderna for 6, BNT for 4 and MCV for 2) were reported with median age of 53.7 years and median onset of 13 days. Furthermore, 364 cases of all-thromboembolic events included 134 pulmonary embolisms (0.00027%) and 113 deep vein thrombosis incidences (0.00023%). On the other hand, 29 cases of cerebral venous sinus thrombosis (CVST) without thrombocytopenia were reported including AZ for 18, Moderna for 8, BNT for 2 and MCV for 1 with a median age of 51 years and median onset of 13 days [20]. CVST with thrombocytopenia has been more observed internationally; however, we also found CVST without thrombocytopenia clinically, and there might be a different mechanism in thrombosis after vaccination. Additionally, the incidence of non-thrombocytopenic thrombosis was 2.36% (2/86 injected doses), which was very high in our transplant series.

The mRNA vaccines were well tolerated and such severe adverse effects were not reported even in the third dose vaccination [21,22]. Our two cases demonstrated that thromboembolic events occurred even without adverse effects after the first Moderna vaccine. Clinicians should remain alert after every vaccination and recognize typical or atypical clinical manifestations of thromboembolic events for early diagnosis and adequate management in patients to reduce any critical damage. In these cases, Moderna-related thrombosis was not always associated with thrombocytopenia, meaning that there might be a different pathway for thrombosis in kidney transplant recipients receiving COVID-19 vaccinations and any judgement cannot be made merely on platelet counts.

4. Conclusions

Nowadays, the COVID-19 pandemic continues to spread with new variants. Protection through vaccinations is essential and another booster might be needed to increase the endogenous antibodies, although any risk of deep vein thrombosis or even pulmonary embolism for these immunocompromised patients must be understood, which might not occur after just the first vaccination.

On the other hand, for recipients of kidney transplantation already at risk of thrombosis by immunosuppressants, balanced evaluation of safety and potential severe adverse effects of vaccinations become even more critical issues with different considerations to the general population. Finally, VITT or TTP are not the only ways where thromboembolic events after COVID-19 vaccinations in kidney transplant patients who are under immunosuppressants therapies might develop. The higher incidence to have thromboembolic events in transplant patients might be the combined synergistic effects of immunosuppressants and COVID vaccinations.

Author Contributions: Conceptualization, C.-S.C., D.-R.H. and Y.-C.H.; investigation, C.-S.C., W.-N.C. and J.-H.L.; data curation, C.-S.C., W.-N.C. and K.-T.H.; writing—original draft preparation, W.-N.C. and Y.-L.L.; writing—review and editing, C.-S.C. and W.-N.C.; supervision, C.-S.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.
Vaccines 2022, 10, 868

References

1. Centers for Disease Control and Prevention: COVID-19 Vaccines for Moderately or Severely Immunocompromised People. Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html (accessed on 12 April 2022).

2. Cines, B.; James, B. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N. Engl. J. Med. 2021, 384, 2254–2256. [CrossRef] [PubMed]

3. Abrignani, M.G.; Murrone, A.; De Luca, L.; Roncon, L.; Di Lenarda, A.; Valente, S.; Caldarola, P.; Riccio, C.; Oliva, F.; Gulizia, M.M.; et al. COVID-19, Vaccines, and Thrombotic Events: A Narrative Review. J. Clin. Med. 2022, 11, 948. [CrossRef] [PubMed]

4. Parums, D.V. SARS-CoV-2 mRNA vaccines and the possible mechanism of vaccine-induced immune thrombotic thrombocytopenia (VITT). Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2021, 27, e932899-1. [CrossRef] [PubMed]

5. Bilotta, C.; Perrone, G.; Adelfio, V.; Spatola, G.F.; Uzzo, M.L.; Argo, A.; Zerbo, S. COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis. Front. Immunol. 2021, 12, 729251. [CrossRef] [PubMed]

6. Von Hundelshausen, P.; Lorenz, R.; Siess, W.; Weber, C. Vaccine-induced immune thrombotic thrombocytopenia (VITT): Targeting pathomechanisms with Bruton tyrosine kinase inhibitors. Thromb. Haemost. 2021, 121, 1395–1399. [CrossRef] [PubMed]

7. Shiravi, A.A.; Ardekani, A.; Sheikhbahaei, E.; Heshmat-Ghahdarijani, K. Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview. Cardiol. Ther. 2021, 11, 13–21. [CrossRef] [PubMed]

8. Abbattista, M.; Martinelli, I.; Peyvandi, F. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites. J. Thromb. Haemost. 2021, 19, 2554–2558. [CrossRef] [PubMed]

9. Tobaigty, M.; MacLure, K.; Elkout, H.; Stewart, D. Thrombotic adverse events reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines: Comparison of occurrence and clinical outcomes in the EudraVigilance database. Vaccines 2021, 9, 1326. [CrossRef] [PubMed]

10. Danovitch, G.M. Handbook of Kidney Transplantation, 6th ed.; Wolter Kluwer: Philadelphia, PA, USA, 2017; pp. 100–163.

11. Al-Nouri, Z.L.; Reese, J.A.; Terrell, D.R.; Vesely, S.K.; George, J.N. Drug-induced thrombotic microangiopathy: A systematic review of published reports. Blood J. Am. Soc. Hematol. 2015, 125, 616–618. [CrossRef] [PubMed]

12. Fortin, M.-C.; Raymond, M.-A.; Madore, F.; Fugère, J.-A.; Piquet, M.; St-Louis, G.; Heber, M.-J. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin–sirolimus combination. Am. J. Transplant. 2004, 4, 946–952. [CrossRef] [PubMed]

13. Cherney, D.Z.I.; Zaltzman, J.S. Mycophenolate mofetil causing deep venous thrombosis in a renal transplant patient with factor V Leiden. Nephrol. Dial. Transplant. 2001, 16, 1702–1704. [CrossRef] [PubMed]

14. Cucchiari, D.; Egri, N.; Bodro, M.; Herrera, S.; Del Risco-Zevallos, J.; Casals-Urquiza, J.; Cofan, F.; Moreno, A.; Kovak, J.; Banon-Maneus, E.; et al. Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am. J. Transpl. 2021, 21, 2727–2739. [CrossRef] [PubMed]

15. Ghady, H.; Mounzer, A.; Andrew, B.; Amy, L.; Kelsey, L.; Rachel, T.; Deborah, K.M.; Melissa, D.C.; Michele, D.S.; et al. Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: The COVICS study. Clin. Infect. Dis. 2022. [CrossRef]

16. Caillard, S.; Chavarot, N.; Bertrand, D.; Kamar, N.; Thaunat, O.; Masset, C.; Hazzan, M.; Gatault, P.; Santantonio, T. Severe systemic thrombosis in a young COVID-19 patient with a rare homozygous prothrombin G20210A mutation. Le Infez. Med. 2021, 29, 259–262. [CrossRef]

17. Castro, R.A.; Frishman, W.H. Thrombotic complications of COVID-19 infection: A review. Cardiol. Rev. 2021, 29, 43–47. [CrossRef] [PubMed]

18. Fiore, J.R.; Ciaramello, M.; Di Stefano, M.; Salvatore Sica, S.; Scarle, M.; D’Errico, M.; Corallo, F.; Lo Caputo, S.; Margaglione, M.; Santantonio, T. Severe systemic thrombosis in a young COVID-19 patient with a rare homozygous prothrombin G20210A mutation. Le Infez. Med. 2021, 29, 259–262. [CrossRef]

19. Taiwan Centers for Disease Control. Available online: https://www.cdc.gov.tw/Category/Page/9jFXNnBe-eFK9ElmRR2Qg (accessed on 17 April 2022).

20. Taiwan Food and Drug Administration. Available online: https://www.fda.gov.tw/TC/siteList.aspx?id=1571 (accessed on 18 April 2022).

21. Marion, O.; Del Bello, A.; Abravanel, F.; Couat, C.; Faguer, S.; Esposito, L.; Hebral, A.L.; Izopet, J.; Kamar, N. Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants. Ann. Intern. Med. 2021, 174, 1336–1338. [CrossRef] [PubMed]

22. Olivier Marion, O.; Del Bello, A.; Abravanel, F.; Couat, C.; Faguer, S.; Esposito, L.; Hebral, A.L.; Izopet, J.; Kamar, N. Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis. Vaccines 2022, 10, 95.